Literature DB >> 27139629

Crystal structures of apo and inhibitor-bound TGFβR2 kinase domain: insights into TGFβR isoform selectivity.

Andrew J Tebben1, Maxim Ruzanov1, Mian Gao2, Dianlin Xie2, Susan E Kiefer2, Chunhong Yan2, John A Newitt2, Liping Zhang3, Kyoung Kim3, Hao Lu4, Lisa M Kopcho4, Steven Sheriff1.   

Abstract

The cytokine TGF-β modulates a number of cellular activities and plays a critical role in development, hemostasis and physiology, as well as in diseases including cancer and fibrosis. TGF-β signals through two transmembrane serine/threonine kinase receptors: TGFβR1 and TGFβR2. Multiple structures of the TGFβR1 kinase domain are known, but the structure of TGFβR2 remains unreported. Wild-type TGFβR2 kinase domain was refractory to crystallization, leading to the design of two mutated constructs: firstly, a TGFβR1 chimeric protein with seven ATP-site residues mutated to their counterparts in TGFβR2, and secondly, a reduction of surface entropy through mutation of six charged residues on the surface of the TGFβR2 kinase domain to alanines. These yielded apo and inhibitor-bound crystals that diffracted to high resolution (<2 Å). Comparison of these structures with those of TGFβR1 reveal shared ligand contacts as well as differences in the ATP-binding sites, suggesting strategies for the design of pan and selective TGFβR inhibitors.

Entities:  

Keywords:  TGFβR1 and TGFβR2 isoform selectivity; TGFβR2 kinase domain; apo and inhibitor-bound structures

Mesh:

Substances:

Year:  2016        PMID: 27139629     DOI: 10.1107/S2059798316003624

Source DB:  PubMed          Journal:  Acta Crystallogr D Struct Biol        ISSN: 2059-7983            Impact factor:   7.652


  7 in total

1.  Discovery of 4-Azaindole Inhibitors of TGFβRI as Immuno-oncology Agents.

Authors:  Yong Zhang; Yufen Zhao; Andrew J Tebben; Steven Sheriff; Max Ruzanov; Mark P Fereshteh; Yi Fan; Jonathan Lippy; Jesse Swanson; Ching-Ping Ho; Barri S Wautlet; Anne Rose; Karen Parrish; Zheng Yang; Andrew F Donnell; Liping Zhang; Brian E Fink; Gregory D Vite; Karen Augustine-Rauch; Joseph Fargnoli; Robert M Borzilleri
Journal:  ACS Med Chem Lett       Date:  2018-10-17       Impact factor: 4.345

2.  Structural biology of the TGFβ family.

Authors:  Erich J Goebel; Kaitlin N Hart; Jason C McCoy; Thomas B Thompson
Journal:  Exp Biol Med (Maywood)       Date:  2019-10-09

3.  Molecular modeling and molecular dynamic simulation of the effects of variants in the TGFBR2 kinase domain as a paradigm for interpretation of variants obtained by next generation sequencing.

Authors:  Michael T Zimmermann; Raul Urrutia; Gavin R Oliver; Patrick R Blackburn; Margot A Cousin; Nicole J Bozeck; Eric W Klee
Journal:  PLoS One       Date:  2017-02-09       Impact factor: 3.240

Review 4.  Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2.

Authors:  Eleanor Williams; Alex N Bullock
Journal:  Bone       Date:  2017-09-12       Impact factor: 4.398

5.  "Let my liver rather heat with wine" - a review of hepatic fibrosis pathophysiology and emerging therapeutics.

Authors:  Carlos G Moscoso; Clifford J Steer
Journal:  Hepat Med       Date:  2019-09-02

6.  TransDTI: Transformer-Based Language Models for Estimating DTIs and Building a Drug Recommendation Workflow.

Authors:  Yogesh Kalakoti; Shashank Yadav; Durai Sundar
Journal:  ACS Omega       Date:  2022-01-12

7.  Novel Transforming Growth Factor-Beta Receptor 1 Antagonists through a Pharmacophore-Based Virtual Screening Approach.

Authors:  Junhao Jiang; Hui Zhou; Qihua Jiang; Lili Sun; Ping Deng
Journal:  Molecules       Date:  2018-10-31       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.